Pituitary GHRH Receptor
Tesamorelin is studied as a stabilized synthetic GHRH analogue that binds the pituitary GHRH receptor and initiates receptor-linked intracellular signaling.
Tesamorelin
Stabilized Synthetic GHRH Analog | Research Grade | Lyophilized Powder
Tested by an Independent Lab
Expédition de la chaîne du froid
COA Included
Paiement SécuriséDiscreet PackagingLivraison internationale
Mode of Action
Tesamorelin Research Overview
Tesamorelin is a stabilized synthetic GHRH analogue studied for pituitary GHRH-receptor activation, receptor-linked intracellular signalling, pulsatile endogenous growth-hormone release and downstream IGF-1 production. Preclinical observations on lipid mobilization and clinical measurements of body composition or visceral adipose tissue must be interpreted within their specific models and populations; a change in visceral fat does not automatically indicate general weight loss. Tesamorelin is not a GLP-1, GIP or glucagon receptor agonist, is not an amylin analogue, and is not directly administered growth hormone. Regulated pharmaceutical specialties may have jurisdiction-specific authorized indications, but the ELIX LABS research product is not equivalent to an approved medicine and is supplied exclusively for laboratory research.
Pulsatile GH Secretion
Receptor activation is investigated for stimulation of endogenous, pulsatile growth hormone secretion rather than delivery of growth hormone itself.
Axe IGF-1 aval
Research evaluates downstream IGF-1 production within the hypothalamic–pituitary–somatomedin axis and its context-dependent biological effects.
Lipid Metabolism
Experimental and clinical research examines lipolysis, lipid mobilization, body composition, and visceral adipose tissue without implying guaranteed weight loss.
GH/IGF-1 Signaling
Activation of pituitary GHRH-receptors and downstream somatomedin-axis responses.
Endogenous Pulsatility
Temporal patterns of endogenous GH release in controlled research models.
Lipid Metabolism
Lipolysis and lipid mobilization assessed under model-specific conditions.
Body Composition
Observations specific to each compartment were interpreted separately from total body-weight change.
Visceral Adipose Tissue
Mesures cliniques et expérimentales évaluées dans leur contexte de preuve spécifique.
What's Included
Reconstruction Guide
How to safely prepare your peptide.
PDF GuideResearch Dosing Guide
Recommended research dosage protocols.
PDF GuideClinical Research Digest
Dernières recherches cliniques et découvertes clés.
PDF GuideMode of Action
Simple visual explanation of how it works.
PDF GuideInstant Digital AccessAvailable immediately after your order is confirmed.
Tesamorelin FAQ
Qu'est-ce que la Tesamoréline?
Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH) studied for its effects on pituitary signaling and the endogenous GH/IGF-1 axis. ELIX LABS supplies it exclusively for laboratory research.
Qu'est-ce que la GHRH?
GHRH is a hypothalamic signaling peptide that acts at the pituitary gland to regulate pulsatile secretion of endogenous growth hormone.
How does Tesamorelin interact with the GHRH receptor?
Tesamorelin is studied as a ligand for the pituitary GHRH receptor. Receptor engagement activates GHRH-linked intracellular pathways associated with endogenous growth hormone release.
How does Tesamorelin influence GH and IGF-1 signaling?
Research examines whether pituitary GHRH-receptor activation increases pulsatile endogenous GH secretion, which can influence downstream IGF-1 production. Responses depend on the model and experimental or clinical context.
La Tesamoréline est-elle la même chose que l'hormone de croissance ?
No. Tesamorelin is a GHRH analog investigated for stimulation of endogenous pituitary GH release; it is not directly administered growth hormone.
Why is Tesamorelin studied in relation to visceral adipose tissue?
The GH/IGF-1 axis can influence lipid metabolism, lipolysis, and body composition. Studies therefore measure visceral adipose tissue in defined populations and controlled settings, without establishing a universal effect.
La recherche sur la graisse viscérale indique-t-elle automatiquement une perte de poids globale ?
No. A change in one fat compartment does not necessarily produce or predict a comparable change in total body weight. Each outcome must be interpreted independently within the study design.
How does Tesamorelin differ from Retatrutide?
Tesamorelin primarily activates the GHRH receptor and modulates endogenous GH/IGF-1 signaling. Retatrutide is being investigated as an agonist of GLP-1, GIP, and glucagon receptors, so their mechanisms and evidence bases are distinct.
How does Tesamorelin differ from Cagrilintide?
Tesamorelin is a GHRH analogue, whereas Cagrilintide is an amylin analogue studied at amylin-receptor complexes. Tesamorelin is not an amylin analogue, and neither comparison implies equivalent outcomes.
How should lyophilized Tesamorelin be stored for research?
Keep sealed lyophilized material refrigerated at 2–8°C, dry and protected from light. Follow the batch documentation and the laboratory’s validated handling and stability procedures.
Le produit ELIX LABS est-il destiné à un usage humain ?
No. This ELIX LABS product is exclusively for laboratory research and is not for human or veterinary use, diagnosis, treatment or consumption. It must not be treated as equivalent to an authorized pharmaceutical product.
Quelle documentation est incluse avec le produit ?
The product includes access to the four listed research resources and available batch-specific analytical documentation, including the Certificate of Analysis.